Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
6 Results for "
ring hydroxylation
" in MedChemExpress (MCE) Product Catalog:
Products (6)
6 Results for "ring hydroxylation" in MCE Product Catalog:
Target:
Research Areas:
Thioacetanilide (N-Phenylthioacetamide) is a sulfur-containing thioamide derivative of acetanilide. Thioacetanilide displays a solvent‑dependent Z/E isomeric distribution, preferring the E conformation in polar hydrogen‑bonding solvents and the Z conformation in halogenated solvents. Thioacetanilide serves as a substrate for metabolic desulfurization and aromatic hydroxylation. Thioacetanilide is mainly metabolized via desulfurization and 4‑hydroxylation of the aromatic ring in Rattus norvegicus, and the released sulfur integrates into the total body sulfur pool. Thioacetanilide is well absorbed in rats, and more than 90% of the dose is excreted in urine as conjugated metabolites after oral administration .
Cat. No.: HY-177148
CAS No.: 134867-97-3
Target:
Research Areas:
G256 is a cytochrome P450 substrate with antiarrhythmic properties. In recombinant monooxygenase systems, G256 undergoes N-hydroxylation of the terminal aminoguanidine nitrogen, as well as ring hydroxylation catalyzed by cytochrome P4502C3. G256 generates N-hydroxyaminoguanidine metabolites via N-hydroxylation in liver microsomal fractions. G256 produces phenol metabolites through ring hydroxylation in both liver microsomal fractions and recombinant cytochrome P450 systems. G256 can be used for research on arrhythmias .
Cat. No.: HY-177148A
CAS No.: 134867-96-2
Target:
Research Areas:
G256 dihydrochloride is a cytochrome P450 substrate with antiarrhythmic properties. In recombinant monooxygenase systems, G256 dihydrochloride undergoes N-hydroxylation of the terminal aminoguanidine nitrogen, as well as ring hydroxylation catalyzed by cytochrome P4502C3. G256 dihydrochloride generates N-hydroxyaminoguanidine metabolites via N-hydroxylation in liver microsomal fractions. G256 dihydrochloride produces phenol metabolites through ring hydroxylation in both liver microsomal fractions and recombinant cytochrome P450 systems. G256 dihydrochloride can be used for research on arrhythmias .
Cat. No.: HY-177148B
CAS No.: 136623-15-9
Target:
Research Areas:
(E/Z)-G256 (dihydrochloride) is an isomer of G256 dihydrochloride (HY-177148A). G256 dihydrochloride is a cytochrome P450 substrate with antiarrhythmic properties. In recombinant monooxygenase systems, G256 dihydrochloride undergoes N-hydroxylation of the terminal aminoguanidine nitrogen, as well as ring hydroxylation catalyzed by cytochrome P4502C3. G256 dihydrochloride generates N-hydroxyaminoguanidine metabolites via N-hydroxylation in liver microsomal fractions. G256 dihydrochloride produces phenol metabolites through ring hydroxylation in both liver microsomal fractions and recombinant cytochrome P450 systems. G256 dihydrochloride can be used for research on arrhythmias .
Target:
Research Areas:
Pyranocoumarin (Compound 13) is a heterocyclic scaffold (coumarin + pyran ring fusion). Pyranocoumarin inhibits the S-warfarin hydroxylation catalyzed by CYP2C9 .
Target:
Research Areas:
Clofexamide (ANP 246) is an orally active antidepressant agent, exhibiting analgesic and anti-inflammatory activity. Clofexamide can be used for the research of depression, inflammatory disorders, peptic ulcer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
